Palivizumab news

All news on Palivizumab (also known as Synagis): plants, production capacities, investments and involved companies.

19 February 2026

Merck Reports Positive Phase 3 Trial Results for ENFLONSIA in High-Risk Infants and Children

ENFLONSIA shows consistent safety and efficacy in high-risk infants over two RSV seasons, supporting expanded use for children under 2.
19 September 2025

Merck's ENFLONSIA™ Recommended by EU CHMP for RSV Prevention in Infants

ENFLONSIA™ awaits EU approval for infant RSV prevention, offering a single-dose option for all weights. Backed by Phase 2b/3 and Phase 3 trials, decision expected by year-end.

Who will be producing Palivizumab in the future?

Find out with chemXplore Alpha

Learn more